Eduardo de Marchena2014-10-30 M.D., F.A.C.C., F.A.C.P., F.S.C.A.I.Professor of Medicine & SurgeryAssociate Dean for International MedicineDirector of Interventional CardiologyUniversity of Miami Miller School of Medicine

Fundamentos: Existem poucos dados comparando diferentes pr&oacute;teses valvares (THV) utilizadas nos implantes percut&acirc;neos de valva a&oacute;rtica (TAVI), sendo que as pr&oacute;teses bal&atilde;o expans&iacute;veis parecem apresentar melhores resultados em rela&ccedil;&atilde;o &agrave;s bal&atilde;o-expans&iacute;veis. O objetivo do estudo foi comparar a performance hemodin&acirc;mica entre as pr&oacute;teses a&oacute;rticas Edwards Sapien XT (bal&atilde;o-expans&iacute;vel) e Medtronic CoreValve (auto-expans&iacute;vel) em pacientes de<a href="https://solaci.org/en/2015/06/24/congress-item-9100/" title="Read more" >...</a>

The CoreValve ADVANCE II Trial is a research study of the best practices to implement this device. Those practices included a careful assessment using scan to choose the right valve size, control the depth of the implant to 6 mm or less in relation to the valve annulus and adherence to international standards for pacemaker<a href="https://solaci.org/en/2015/06/24/congress-item-8995/" title="Read more" >...</a>

This study evaluated the safety and efficacy of the new repositionable self-expanding valve. The primary end point was all-cause mortality and stroke at 30 days. 60 patients were included and the possibility for reposition was used 22 times between 12 recaptures and 10 re-sheathed of the valve. All maneuvers were carried out successfully. A 30<a href="https://solaci.org/en/2015/06/24/congress-item-9009/" title="Read more" >...</a>

Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR). There is little consensus regarding the cost-effectiveness for transcatheter versus surgical replacement.&nbsp; The present study was aimed to quantify the quality of life, adjusted survival for quality of life, resource utilization,<a href="https://solaci.org/en/2015/06/24/congress-item-8232/" title="Read more" >...</a>

This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery.&nbsp; The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for<a href="https://solaci.org/en/2015/06/24/congress-item-8239/" title="Read more" >...</a>

The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve Core with conventional surgery in patients at high surgical risk. Patients with a valve area &lt; 0.8 cm2 , valvular index &le; 0.5 cm2 , a mean gradient of &nbsp;&gt; 40 mmHg or peak speeds above 4m /s<a href="https://solaci.org/en/2015/06/24/congress-item-7616/" title="Read more" >...</a>

So far, there had been no published randomized studies comparing balloon-expandable Edwards&rsquo;s prosthesis and self-expandingCoreValve. The aim of this study was to compare the results between the two thin aortic prosthesis in high-risk surgical patients with severe symptomatic aortic stenosis undergoing valve replacement by percutaneous transfemoral access. This was a multicenter work (five centers in<a href="https://solaci.org/en/2015/06/24/congress-item-7630/" title="Read more" >...</a>

Percutaneous aortic valve implantation ( TAVI ) recently demonstrated its superiority over medical treatment in patients with severe aortic stenosis and high surgical risk. Furthermore patients receiving TAVI showed a survival surgery equivalent to one year. This study included 471 patients with symptomatic severe aortic stenosis discarded of surgery due &nbsp;a very high risk. The<a href="https://solaci.org/en/2015/06/24/congress-item-6244/" title="Read more" >...</a>